Add to MyYahoo RSS

AstraZeneca Group News

News on AstraZeneca Group (Ticker: AZN) continually updated from thousands of sources around the net.

1 min ago | Seeking Alpha

Nektar Therapeutics Has More To Give

Investors should know within a month whether the FDA will approve Movantik, Nektar's opioid-induced constipation drug partnered with AstraZeneca that has $1B+ potential.


Related Topix: Startups, Nektar Therapeutics, Healthcare Law, Law, Medicine, Constipation, Health, AstraZeneca, Biotech, Healthcare Industry, Oncology

4 hrs ago | BioSpace

Pfizer Inc. Eyes Possible Actavis Bid Whilst Weighing Next Steps Over AstraZeneca PLC

Pfizer Inc. isn't giving up on striking an overseas takeover to cut its tax rate and gain a new pipeline of drugs, even as the potential cost of acquiring AstraZeneca Plc rises.


Related Topix: Pfizer, Biotech, Medicine, Healthcare Industry, AstraZeneca

8 hrs ago | Hispanic Business

Astrazeneca Announces Partnership with Illumina to Develop Next...

In the first instance, intends to apply Illumina's cutting-edge technology to a novel companion diagnostic test in pivotal studies for one of its investigational oncology compounds.


Related Topix: Scientific Instruments, Biotech, Illumina, Medicine, Healthcare Industry, Oncology, Genetics

12 hrs ago | Live Charts

London close: Astrazeneca leads FTSE higher on bid speculation

Increased speculation regarding ECB action, on the heels of weaker than forecast readings on the Eurozone economy, were offset by a weak report on UK retail sales.


Related Topix: Biotech, Healthcare Services Group, Apparel, Financial Markets

15 hrs ago |

Why AstraZeneca (AZN) Stock Is Higher Today

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.


Related Topix: AstraZeneca, Biotech, Medicine, Healthcare Industry, Mozilla, Financial Markets

18 hrs ago |

AstraZeneca plc Receives "Hold" Rating from Beaufort Securities

AstraZeneca plc opened at 4375.50 on Thursday. AstraZeneca plc has a 52 week low of GBX 3086.50 and a 52 week high of GBX 5750.00.


Related Topix: AstraZeneca, Biotech, Medicine, Healthcare Industry

22 hrs ago | Customer Interaction Solutions

Illumina Announces Strategic Partnerships with AstraZeneca, Janssen...

The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine.


Related Topix: Scientific Instruments, Biotech, Illumina, Medicine, Healthcare Industry, AstraZeneca, Oncology

Wed Aug 20, 2014


AstraZeneca PLC, Mitsubishi Tanabe Pharma Corporation Link Up For Diabetes Research

AstraZeneca and Mitsubishi Tanabe Pharma said on Wednesday they said signed a three-year research collaboration into diabetic nephropathy, or kidney failure due to diabetes.


Related Topix: AstraZeneca, Biotech, Medicine, Health, Healthcare Industry, Diabetes

Customer Interaction Solutions

Clinigen Group Further Strengthens Oncology Support Portfolio with...

Clinigen Group plc the specialty global pharmaceutical company today announces the acquisition of the global rights to the oncology support therapy, Ethyol from AstraZeneca.


Related Topix: Oncology, Medicine, Ethyol, Amifostine (generic), Biotech, Ovarian Cancer, Health, Food and Drug Administration

Tue Aug 19, 2014

Sys-Con Media

The Zacks Analyst Blog Highlights: Tesla Motors, CarMax,...

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.


Related Topix: Auto Dealers, Retail, CarMax Group, Tesla Motors, Startups, Financial Markets, OReilly Automotive, Auto Parts, AstraZeneca, Biotech, Medicine, Healthcare Industry

The Negative Impact Of Pfizer's Mergers And Budget Cuts On Cancer R&D

"And then, I don't know if Mikael Dolsten is on the call, but just a question on business development, analyzing, outlicensing activity.


Related Topix: Biotech, Healthcare Law, Law, Medicine, Health, Breast Cancer, Herceptin, Trastuzumab (generic), Oncology, Mesothelioma

How Will AstraZeneca (AZN) Stock Respond To U.S. Clearing Heart Drug Trial?

The company said the government was closing its investigation into the 18,000-patient study and no further action was planned.


Related Topix: AstraZeneca, Biotech, Medicine, Healthcare Industry, Financial Markets, Business News

Mon Aug 18, 2014


Us Doj Closes Investigation into Plato

UNITED STATES DEPARTMENT OF JUSTICE CLOSES INVESTIGATION INTO PLATO CLINICAL TRIAL FOR BRILINTA AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with Brilinta .


Related Topix: US News, Biotech, Stroke, Medicine, Health, Heart Attack, Food and Drug Administration, Aspirin (generic), Bayer, Alka-Seltzer

Recent Analysts' Ratings Updates for AstraZeneca plc

A number of stock research firms have changed their ratings and price targets for AstraZeneca plc during the last seven days: AstraZeneca plc had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co..


Related Topix: AstraZeneca, Biotech, Medicine, Healthcare Industry, Banking, JP Morgan Chase

Sun Aug 17, 2014

Seeking Alpha

2nd Half Of 2014 Biotechnology Catalysts--Part 4

Through knowing when PDUFA decisions are going to be made, investors can benefit from the increased momentum and share price heading into the decision.


Related Topix: Startups, Nektar Therapeutics, AstraZeneca, Biotech, Medicine, Healthcare Industry

Thu Aug 14, 2014

Seeking Alpha

Why GlaxoSmithKline Is A Tempting Buy

By now, most investors know all the problems facing pharmaceutical giant GlaxoSmithKline .


Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, Pfizer, AstraZeneca


AstraZeneca PLC Starts Late-Stage Asthma Drug Trial

Astrazeneca Advances Tralokinumab To Phase III In Severe Asthma Thursday, 14 August 2014: AstraZeneca today announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company's global biologics research and development arm.


Related Topix: Medicine, Asthma, Health, Biotech, MedImmune, Healthcare Industry

Wed Aug 13, 2014

Seeking Alpha

Dynavax Is More Than Just HEPLISAV

Successful Phase 1 study of AZD1419 seemed to be a side note; yet AZD1419 may be the forgotten catalyst for Dynavax over the next year.


Related Topix: Startups, Dynavax Technologies, Healthcare Law, Law, Biotech, GlaxoSmithKline

Wall Street Journal

AstraZeneca Gets Good Results From Gout Drug Trials

AstraZeneca PLC reported on Wednesday positive results from three combination Phase III clinical trials of treatments for patients with gout, an inflammatory arthritis.


Related Topix: AstraZeneca, Biotech, Medicine, Health, Healthcare Industry, Gout

Mon Aug 11, 2014

Seeking Alpha

For Lexicon Pharmaceuticals, No News Remains Bad News

Lexicon updates investors on its second quarter results, but still has no partner to develop LX4211 in Type 2 diabetes.


Related Topix: Biotech, Lexicon Pharmaceuticals, Medicine, Lexicon Genetics, Healthcare Industry, Diabetes, Health, Arena Pharmaceuticals, Johnson and Johnson


Ashburn Jobs